Endo International (ENDP) Tops Q1 EPS by 12c, Affirms Gudiance

Endo International (NASDAQ: ENDP) reported Q1 EPS of $0.67, $0.12 better than the analyst estimate of $0.55. Revenue for the quarter came in at $701 million versus the consensus estimate of $691.83 million.

For the full twelve months ending December 31, 2018, at current exchange rates, Endo affirms its previously provided guidance on revenue, adjusted diluted EPS from continuing operations and adjusted EBITDA from continuing operations. The Company estimates:

• Total revenues to be between $2.6 billion and $2.8 billion;
• Adjusted diluted EPS from continuing operations to be between $2.15 and $2.55; and
• Adjusted EBITDA from continuing operations to be between $1.2 billion and $1.3 billion.

For earnings history and earnings-related data on Endo International (ENDP) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c